Last updated: March 19, 2026
What is NDC 57664-0666?
NDC 57664-0666 represents a specific pharmaceutical product. Based on available data, it corresponds to Remdesivir (Veklury), an antiviral medication approved for the treatment of COVID-19. The drug's packaging typically includes a 100 mg lyophilized powder for infusion.
Market Landscape
Historical Sales and Usage
Remdesivir's market penetration increased significantly after emergency use authorizations in 2020 and subsequent full approval by the FDA in October 2020. Peak sales occurred in 2021, driven by COVID-19 treatment demand. Sales plateaued post-pandemic, with manufacturers adjusting supply levels.
Key Manufacturers
- Gilead Sciences Inc. produces Veklury as the sole manufacturer.
- Gilead's global sales of Remdesivir reached an estimated $3.8 billion in 2021, accounting for the majority of pandemic-related antiviral revenue.
Market Penetration
- Input from market research indicates rapid adoption in hospital settings.
- The drug maintains strong presence in hospitals with high COVID-19 caseloads.
- Competition from other antivirals remains limited due to patent protections and regulatory exclusivity.
Price Analysis
Historical Pricing
- The wholesale acquisition cost (WAC) per 100 mg vial stood around $390 in 2021.
- Treatment involves 6 vials (6 x 100 mg doses), leading to an initial treatment cost of approximately $2,340 per patient.
Reimbursement and Net Pricing
- Payer negotiations and discounts reduce net prices.
- Hospitals and health systems pay roughly $300–$350 per vial after negotiations, translating to treatment costs between $1,800 and $2,100.
Pricing Trends
- Prices stabilized after initial fluctuations during 2020-2021.
- Limited price decreases due to sustained demand and limited generic competition.
Future Price Projections
Factors Influencing Prices
- Patent Life & Exclusivity: Gilead holds patent protection until at least 2030.
- Generic Entry: As of now, no approved generics exist; patent litigation or biosimilar development may alter this.
- Market Demand: Declines in COVID-19 cases could reduce demand, pressuring prices.
- Regulatory Changes: Policy shifts or expanded indications could influence pricing strategies.
Projected Price Range (Next 5 Years)
| Year |
Expected WAC per Vial |
Notes |
| 2023 |
$390–$410 |
Slight fluctuations based on supply and demand |
| 2024 |
$385–$405 |
Anticipated stabilization |
| 2025 |
$380–$400 |
Potential slight decrease if biosimilars enter |
| 2026 |
$375–$395 |
Competitive pressures may influence pricing |
| 2027 |
$370–$390 |
Possible decline with increased biosimilar activity |
Competitive and Market Dynamics
The absence of biosimilar competition as of 2023 limits downward pressure. If biosimilar development accelerates and gains approval, prices could decline by approximately 15–25% within three to five years.
Risks and Opportunities
- Risks: Patent challenges, market saturation, post-pandemic demand reduction.
- Opportunities: Expanded indications, increased global adoption, price negotiations driven by health systems.
Regulatory and Policy Environment
- The US government has purchased large stockpiles for pandemic response, influencing supply and pricing.
- International markets face different pricing pressures, with some countries engaging in price negotiations or compulsory licensing.
Summary
| Aspect |
Status/Outlook |
| Market Size |
Approximately $3.8 billion in 2021 (Gilead) |
| Pricing Trend |
Stable, with slight potential reductions |
| Patent Status |
Patent protection until at least 2030 |
| Competitive Risk |
Moderate; biosimilars may enter by late 2020s |
| Future Prices |
Expected to decline gradually, with margins narrowing |
Key Takeaways
- Gilead's remdesivir (NDC 57664-0666) has maintained a strong market position since 2020.
- Pricing has been relatively stable but could decline marginally with biosimilar competition and changing demand.
- Lack of current biosimilar options limits immediate price reductions.
- US and international policies significantly influence market dynamics and pricing.
- Long-term profitability depends on patent protections and potential new indications.
FAQs
1. Will remdesivir's price decrease significantly in the next five years?
Price reductions are expected but may be modest (10–20%), driven by biosimilar developments and market demand fluctuations.
2. How does patent protection influence future pricing?
Patent protection until at least 2030 maintains exclusivity, limiting biosimilar competition and supporting stable or slightly declining prices.
3. Are there biosimilars or generics in development?
As of 2023, no biosimilars have gained approval; development efforts are ongoing, with potential approval likely in late 2020s.
4. How do international markets compare in terms of price?
Many countries negotiate prices lower than US WAC; some utilize reference pricing or compulsory licensing to reduce costs.
5. What factors could impact the demand for remdesivir?
Decline in COVID-19 cases, emergence of new treatments, and regulatory decisions on expanding indications could reduce demand.
References
- Gilead Sciences. (2022). Veklury (Remdesivir) Product Info. Retrieved from https://www.gilead.com
- IQVIA. (2022). Summary Report on COVID-19 Treatments.
- US FDA. (2020). Emergency Use Authorization for Remdesivir. Retrieved from https://www.fda.gov
- Statista. (2022). COVID-19 Antiviral Market Data.
- Deloitte. (2022). Biopharma Patent Cliff Report.
[1] Gilead Sciences. (2022). Veklury (Remdesivir) Product Info.
